Table 1:
Characteristics of all patients included in the analysis
| Characteristic | N (%) |
|---|---|
| N | 104 |
| Men (%) | 51 (49%) |
| Median age at transplant, years (range) | 58 (21–78) |
| Number of patients with molecular and flow analysis | |
| Molecular analysis at diagnosis | 58 (55.8) |
| Molecular analysis pre-HCT | 83 (79.8) |
| Paired molecular analysis at diagnosis and pre-HCT | 47 (45.2) |
| Flow MRD analysis pre-HCT | 77 (74.0) |
| Paired flow and molecular analysis pre-HCT | 62 (59.6) |
| AML characteristics | |
| Primary AML | 65 (62.5) |
| Secondary AML, prior disease | 39 (37.5) |
| Prior MDS | 21 |
| Prior MPN | 7 |
| Prior CMML | 0 |
| Therapy related AML ^ | 15 |
| CIBMTR Cytogenetics Grouping | |
| Favorable | 2 (1.9) |
| Intermediate | 88 (84.6) |
| Adverse | 14 (13.5) |
| Remission status at time of HCT | |
| CR1 | 59 (56.7) |
| CR2 | 9 (8.7) |
| CR3 | 1 (1.0) |
| CRi | 21 (20.2) |
| Not in CR | 14 (13.5) |
| DRI | |
| Low | 2 (1.9) |
| Intermediate | 71 (68.3) |
| High | 30 (28.8) |
| Very high | 1 (1.0) |
| HCT-CI | |
| <3 | 51 (49) |
| ≥3 | 53 (51) |
| Stem cell source | |
| Peripheral blood stem cells | 73 (70.2) |
| Bone marrow derived stem cells | 12 (11.5) |
| Cord blood | 19 (18.3) |
| CD34+ selection | 29 (27.9) |
| HLA match # | |
| Fully matched | 72 (69.2) |
| Mismatched | 32 (30.8) |
| Conditioning intensity | |
| Ablative | 59 (56.7) |
| Reduced intensity | 45 (43.3) |
| Transplant | |
| First | 95 (91.3) |
| Second | 9 (8.7) |
| Outcomes | |
| Relapse, N (%) | 22 (21.2) |
| Deceased, N (%) | 36 (34.6) |
| Cause of death | |
| Relapse | 13 (12.5) |
| Infection | 10 (9.6) |
| GVHD | 6 (5.8) |
| Toxicity | 2 (1.9) |
| Organ failure | 4 (3.8) |
| Unknown | 1 (0.8) |
^
2 patients developed therapy related AML after initial diagnosis with therapy related MDS
*
15 patients did not have available FLT3 mutation testing in the setting of a normal karyotype and thus could not be categorized by the NCCN AML classification.
#
Number of mismatches at high resolution at HLA class 1 (A, B, C) and class 2 (DR and DQ). All cord blood transplants were mismatched.